Please login to the form below
Jazz Pharma
This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Jazz licensed lurbinectedin from
Latest news
-
Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs
UK-based Redx Pharma has signed a research collaboration with Jazz Pharmaceuticals focused on discovering and developing drug candidates for two new cancer targets. ... We look forward to collaborating with Jazz on new targeted therapies for patients who
-
Syncona start-up Quell Therapeutics appoints chief exec
Iain McGill. Iain McGill has been recruited from his role as senior vice president Europe and Rest of World for Jazz Pharmaceuticals, the specialist pharma company, best known in Europe for ... He was part of the management team which
-
Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy
The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes,” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.
-
Jazz Pharma bags FDA approval for rare disease drug
The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.
-
Baxter buoys cancer presence with $900m Oncaspar deal
disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
$11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.
-
Pharma deals in March 2015
The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
EUSA Pharma appoints Lee Morley as its new chief executive
EUSA's new CEO Morley comes to the company from Jazz, where he was vice president, head of commercial for Europe and International Markets, with responsibility for the original EUSA Pharma ... business. Prior to his time with Jazz, and before that the pre
-
EUSA founder joins Oxford BioTherapeutics as chairman
This company was later sold to Jazz Pharma in 2012 for $700m. ... Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
